Anti-SARS-CoV S Recombinant Antibody (CR3022) (CAT#: MRO-1214LC)

Ozer, Egon A., et al. "Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria." Nature communications 13.1 (2022): 688.

This study focused on the genomic surveillance of SARS-CoV-2 in Nigeria, particularly in Oyo state, from July 2020 to August 2021. It involved whole-genome sequencing of 378 SARS-CoV-2 isolates, revealing the dominance of the Alpha (B.1.1.7) and Eta (B.1.525) lineages during early 2021. The research highlighted that Eta lineage outcompeted Alpha and persisted even after the introduction of the Delta variant. The study used pseudotyped virus systems to demonstrate that mutations in the Spike protein of Eta isolates enhanced viral entry and reduced the neutralization capacity of antibodies from previously infected individuals. However, antibodies from vaccinated individuals remained effective. The findings emphasized the need for ongoing genomic surveillance to understand and mitigate the impact of SARS-CoV-2 variants in under-sampled regions.
In this study, Creative Biolabs provided the anti-RBD antibody CR3022 (Cat# MRO-1214LC), used to create a standard curve for ELISA assays. This antibody played a crucial role in quantifying the binding capacity of serum antibodies to the receptor-binding domain (RBD) of the virus. The accurate measurement of antibody responses was vital for assessing the immune evasion capabilities of the Eta lineage and the effectiveness of vaccine-induced immunity against this variant. The contribution of Creative Biolabs' product significantly enhanced the reliability and accuracy of the study's immunological assessments .

Gunawardana, Manjula, et al. "Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance study." Communications medicine 2.1 (2022): 129.

The study aimed to deeply understand the early dynamics of SARS-CoV-2 infection and the associated immune responses in unvaccinated individuals. Conducted from November 2020 to March 2021, it monitored nine participants intensely over three months. This longitudinal surveillance revealed rapid early viral replication with a median doubling time of 3.1 hours, followed by a slow and varied clearance phase. The study employed Bayesian modeling to describe these kinetic processes, providing valuable insights into viral transmission and infection progression, which are crucial for public health measures and clinical management of COVID-19.
Creative Biolabs significantly contributed to this study by providing crucial reagents for antibody quantification. Specifically, they supplied the control anti-SARS-CoV S antibody CR3022 (Cat#: MRO-1214LC) in IgG, IgM, and IgA formats (Cat#: N/A). This antibody was essential in the enzyme-linked immunoassay (ELISA) used to measure serum anti-receptor-binding domain (RBD) antibodies, enabling the accurate assessment of humoral immune responses in the participants. The precision and reliability of these measurements were pivotal in understanding the temporal decay profiles of different antibodies and the overall immune response dynamics in the study.

Simons, Lacy M., et al. "De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients." Transplant Infectious Disease 24.6 (2022): e13914.

This study investigates the emergence of SARS-CoV-2 spike mutations in immunosuppressed patients with persistent infections. The research focused on two patients, referred to as Patient A and Patient B, who both experienced prolonged SARS-CoV-2 infections. Nasopharyngeal and plasma specimens were collected over time to analyze viral mutations. Whole genome sequencing revealed the intrahost evolution of spike mutations, including E484K, E484Q, and deletions at positions 241-243. These mutations were linked to reduced neutralization by antibodies and impaired viral entry efficiency. The study emphasizes the role of persistent infections in the evolution of SARS-CoV-2 variants and highlights the need for ongoing antiviral drug development.
Creative Biolabs contributed significantly to this research by providing the anti-RBD antibody CR3022 (Cat# MRO-1214LC), used in enzyme-linked immunoassays (ELISA) to quantify antibody titers against the spike protein's receptor-binding domain. This antibody was crucial in determining the immune response of the patients, specifically in assessing the levels of antibodies targeting the spike protein. The use of CR3022 enabled the researchers to evaluate the impact of the emergent mutations on antibody neutralization, thus playing a key role in understanding how these mutations facilitate immune escape.

Huo, Jiandong, et al. "Neutralization of SARS-CoV-2 by destruction of the prefusion spike." Cell host & microbe 28.3 (2020): 445-454.

The study investigated the neutralization capabilities of the CR3022 monoclonal antibody against SARS-CoV-2. The researchers determined that CR3022 binds tightly to the receptor-binding domain (RBD) of the virus, demonstrating a unique mechanism of action. Unlike other antibodies that block the virus by preventing it from binding to the ACE2 receptor, CR3022 destabilizes the virus's spike protein, which leads to its neutralization. This study utilized surface plasmon resonance (SPR) and bio-layer interferometry (BLI) to measure the binding kinetics, and plaque-reduction neutralization tests (PRNT) to evaluate the antibody's efficacy. The findings suggest that CR3022 could serve as a valuable tool in the development of therapeutic strategies against COVID-19 due to its ability to neutralize the virus through a different mechanism than other known antibodies.
Creative Biolabs contributed significantly to this study by providing the CR3022 monoclonal antibody (Cat# MRO-1214LC). This antibody was crucial for the neutralization assays, enabling the researchers to demonstrate its unique neutralization mechanism. The study highlights the importance of CR3022 in understanding SARS-CoV-2's behavior and potential therapeutic interventions, underscoring the value of the high-quality reagents provided by Creative Biolabs in advancing this critical research.

Tan, Xiaotian, et al. "Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation." Biosensors and Bioelectronics 169 (2020): 112572.

This study presents a novel microfluidic ELISA technology designed for the rapid and sensitive detection of SARS-CoV-2 specific IgG antibodies in human serum. The primary objective of the research was to develop a portable diagnostic tool that can provide quantitative results within 15 minutes using only a small sample volume. The researchers identified a humanized monoclonal IgG with high binding affinity and specificity for SARS-CoV-2 S1 protein to serve as a calibration standard. By using this technology, they measured the abundance of anti-SARS-CoV-2 S1 IgG in convalescent serum from COVID-19 patients, facilitating the selection of suitable donors for convalescent plasma therapy. The study demonstrated that this technology could also detect SARS-CoV-2 antigens with high sensitivity, suggesting its potential applications in diagnostics and monitoring.
Creative Biolabs contributed significantly to this research by providing the recombinant CR3022 therapeutic antibody (Cat#: MRO-1214LC), which was used in the study for calibration and comparison purposes. The provision of this antibody was crucial for establishing the assay's accuracy and reliability in detecting SARS-CoV-2 specific antibodies. By supplying this high-quality reagent, Creative Biolabs enabled the researchers to achieve consistent and reproducible results, thereby enhancing the overall efficacy of the microfluidic ELISA platform in evaluating convalescent serum and potentially other COVID-19 related diagnostic applications.

Pillarsetty, Nagavarakishore, et al. "Oncology-inspired treatment options for COVID-19." Journal of Nuclear Medicine 61.12 (2020): 1720-1723.

This study explores the potential of the human monoclonal antibody CR3022 as a molecularly targeted radiotherapeutic agent against SARS-CoV-2, the virus responsible for COVID-19. CR3022 was labeled with iodine-131 (131I), a radioactive isotope, and its binding to the virus was assessed. The study demonstrated that 131I-CR3022 binds selectively to the SARS-CoV-2 spike protein, making it a promising candidate for both therapeutic and diagnostic purposes. The binding efficiency of the radiolabeled antibody was confirmed through a bead-based assay, indicating its potential use in Auger radiotherapy, which could inactivate the virus while minimizing damage to surrounding tissues. This approach could enhance the efficacy of COVID-19 treatments, especially when used in combination with other therapies.
Creative Biolabs significantly contributed to this research by providing the CR3022 antibody (Cat#: MRO-1214LC). The antibody, essential for the study, was successfully conjugated with iodine-131, maintaining a high purity of over 98% and specific activity of 292 MBq/mg. The high-quality antibody enabled the researchers to achieve selective and potent binding to the SARS-CoV-2 spike protein, thus facilitating the exploration of 131I-CR3022 as a targeted radiotherapeutic agent. This contribution was crucial for the study's success, highlighting Creative Biolabs' role in advancing innovative COVID-19 treatments.

Dzimianski, John V., et al. "Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry." Scientific reports 10.1 (2020): 21738.

This study focuses on developing a novel serological testing method to detect SARS-CoV-2 antibodies using biolayer interferometry (BLI-ISA). The researchers utilized the spike receptor-binding domain (RBD) antigen due to its high selectivity for SARS-CoV-2 antibodies and its correlation with virus neutralization. The BLI-ISA method was optimized to measure antigen-specific antibodies in plasma efficiently, providing a rapid, semi-quantitative evaluation. This new assay holds potential for various applications, including serosurveillance studies, evaluating antibody responses to infection and vaccination, and potentially serving as a diagnostic platform for assessing plasma antibody levels to guide convalescent plasma therapy donations.
Creative Biolabs significantly contributed to this study by supplying the Anti-SARS-CoV S Therapeutic Antibody CR3022 (Cat# MRO-1214LC). This antibody played a crucial role as a positive control in the ELISA and BLI-ISA experiments, enabling the accurate measurement and validation of antibody reactivity against the SARS-CoV-2 spike RBD. The inclusion of this reagent ensured the reliability and accuracy of the serological tests, facilitating the development of a robust and sensitive diagnostic tool​.

Ahn, Terrie S., et al. "Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2." Journal of Allergy and Clinical Immunology 147.3 (2021): 876-877.

This study investigates whether commercial pre-pandemic intravenous immunoglobulin (IVIG) contains cross-reactive antibodies that can bind and neutralize SARS-CoV-2. The researchers tested 82 samples from four different brands manufactured in the United States and Europe for their ability to bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Although all samples showed cross-reactive antibodies, none demonstrated the capacity to neutralize the virus. This suggests that while IVIG can bind to SARS-CoV-2, it does not prevent viral infection. The study also explored the potential non-neutralizing effects of IVIG, such as complement fixation and antibody-dependent cellular cytotoxicity (ADCC), which might still provide therapeutic benefits.
Creative Biolabs contributed to this study by providing the anti-spike antibody CR3022 (Cat#: MRO-1214LC), which was used as a positive control in the experiments. This specific antibody was crucial in validating the binding assays, allowing the researchers to compare the binding efficacy of the commercial IVIG samples. By using CR3022, the study could accurately assess the presence of cross-reactive antibodies and their binding capabilities, thus highlighting the role of Creative Biolabs' product in ensuring the reliability and accuracy of the experimental results.

Demonbreun, Alexis R., et al. "Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure." JCI insight 6.9 (2021).

This study investigated the prevalence and durability of IgG antibodies against SARS-CoV-2 in a diverse urban population. Conducted between June and December 2020, the research recruited 7935 participants through electronic advertising and minimal-contact methods. Participants provided self-sampled dried-blood spots (DBS) for laboratory analysis of IgG antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The findings revealed an overall seroprevalence of 17.9%, indicating a significant underestimation of COVID-19 exposure when relying solely on viral testing. The study demonstrated that asymptomatic and mildly symptomatic individuals produced IgG levels comparable to those documented in non-hospitalized COVID-19 cases, suggesting a widespread exposure across the community.
Creative Biolabs played a crucial role in this study by supplying the CR3022 antibody (Cat# MRO-1214LC), which was essential for the quantitative measurement of anti-RBD IgG levels. This antibody was used to calibrate the ELISA protocol, allowing the researchers to accurately quantify the concentration of IgG in the participants' samples. The high specificity and sensitivity of the CR3022 antibody enabled the reliable detection and measurement of SARS-CoV-2 exposure in the studied population, significantly contributing to the understanding of antibody persistence and the immune response to the virus.

Rauch, Susanne, et al. "mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents." npj Vaccines 6.1 (2021): 57.

The study investigates the efficacy and safety of the mRNA-based SARS-CoV-2 vaccine candidate, CVnCoV, developed by CureVac. The CVnCoV vaccine encodes the full-length, pre-fusion stabilized spike protein of SARS-CoV-2 and is encapsulated in lipid nanoparticles. The study demonstrates that CVnCoV induces robust humoral and cellular immune responses, leading to high titers of virus-neutralizing antibodies and balanced T-cell responses in rodent models. Vaccinated hamsters showed significant protection from SARS-CoV-2 challenge, evidenced by the absence of viral replication in the lungs and no signs of vaccine-enhanced disease, even at suboptimal doses. These findings support the potential of CVnCoV as a potent and safe vaccine candidate against COVID-19.
Creative Biolabs played a crucial role in this research by supplying the Human anti-SARS-CoV S antibody (Cat# MRO-1214LC) used for specific S protein expression assessment. This product was instrumental in verifying the protein's correct expression and modification, essential for the vaccine's efficacy testing. The accurate and reliable detection of the SARS-CoV-2 spike protein facilitated the comprehensive evaluation of the immune responses induced by CVnCoV, contributing significantly to the study's overall success.

Dawson, Erica D., et al. "Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses." Journal of Virological Methods 291 (2021): 114111.

This study focused on the development and validation of a multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses, specifically the VaxArray Coronavirus (CoV) SeroAssay. The assay aims to enhance clinical trials by providing rapid, sensitive, and precise quantification of IgG antibodies against nine coronavirus spike antigens. The study demonstrated the assay's capability to measure antibody responses with high precision and accuracy, achieving a lower limit of quantification ranging from 0.3 to 2.0 ng/mL and a linear dynamic range of 76 to 911-fold. Clinical performance was evaluated using 263 human serum samples, yielding a positive percent agreement (PPA) of 98.5% and a negative percent agreement (NPA) of 100%. This assay is particularly useful for monitoring antibody responses in COVID-19 vaccine candidates, streamlining the process of understanding immune responses post-vaccination.
Creative Biolabs provided the CR3022 monoclonal antibody targeting the spike proteins of SARS-CoV-1 (Cat#: MRO-1214LC), which was used in the study to evaluate the specificity and linear dynamic range of the VaxArray CoV SeroAssay. The CR3022 antibody specifically binds to the nCoV(ii) receptor binding domain (RBD) antigen and the SARS antigen. The inclusion of this antibody was crucial in demonstrating the assay's ability to accurately measure antibody responses to multiple coronavirus antigens. The use of Creative Biolabs' antibody enabled the researchers to validate the performance of the assay, ensuring its reliability and precision in detecting and quantifying antibodies, thereby contributing significantly to the study's success.

Ibarrondo, F. Javier, et al. "Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19." New England Journal of Medicine 383.11 (2020): 1085-1087.

The study focused on the rapid decay of anti-SARS-CoV-2 antibodies in individuals who recovered from mild COVID-19. Conducted with 34 participants, most of whom had mild symptoms, the research aimed to measure and quantify the levels of IgG antibodies targeting the spike receptor-binding domain over a period of up to 119 days post-symptom onset. The study found that antibody levels decreased significantly over time, raising concerns about the longevity of humoral immunity in those with mild COVID-19 and suggesting potential implications for immunity passports, herd immunity, and vaccine durability.
Creative Biolabs played a crucial role in this research by providing the control monoclonal IgG CR3022 (Cat#: MRO-1214LC) used in the enzyme-linked immunosorbent assay (ELISA) to detect and quantify the anti-SARS-CoV-2 spike receptor-binding domain IgG levels. The use of CR3022 was essential in the precise quantification of antibody levels, which enabled the study to accurately track the rate of antibody decay in the participants.

Tan, Xiaotian, et al. "Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples." BioRxiv (2020): 2020-04.

This study presents the development of a microfluidic ELISA technology designed for the rapid, quantitative, and sensitive detection of SARS-CoV-2 biomarkers. By using SARS-CoV-2 specific IgG and viral antigens spiked in serum as a model system, the researchers aimed to provide a point-of-care diagnostic tool that overcomes the limitations of current popular detection methods, such as lateral-flow test strips and conventional ELISA. The microfluidic ELISA device requires minimal sample volumes, is highly portable, and delivers results within 15-20 minutes. This innovative approach not only facilitates the rapid analysis of COVID-19 patients and vaccine recipients but also allows for the swift affinity evaluation of monoclonal anti-S1 antibodies.
Creative Biolabs played a crucial role in this study by providing essential reagents and antibodies that were pivotal to the research. Specifically, the study utilized the human-cell-expressed SARS-CoV Spike S1-His recombinant protein (Cat#: VAng-Wyb7337) and the recombinant CR3022 therapeutic antibody (Cat#: MRO-1214LC), both supplied by Creative Biolabs. These products were instrumental in the detection and characterization of SARS-CoV-2 specific IgG, contributing significantly to the development and validation of the microfluidic ELISA platform. The availability and quality of these reagents ensured the accuracy and reliability of the results, ultimately aiding in the advancement of rapid diagnostic technologies for COVID-19.